Novel xenograft models to study racial differences in myeloma progression

$311,399P20FY2022GMNIH

Univ Of Arkansas For Med Scis, Little Rock AR

Investigators

Linked publications & trials

Paper 39605211 Paper 39566076 Paper 39344417 Paper 39312185 Paper 39222062 Paper 39171528 Paper 39154858 Paper 39019412 Paper 38960295 Paper 38788812 Paper 38746391 Paper 38558984 Paper 38479598 Paper 38401618 Paper 38385272 Paper 38314723 Paper 38014179 Paper 37981834 Paper 37960223 Paper 37760681 Paper 37751740 Paper 37660163 Paper 37581932 Paper 37574201 Paper 37535708 Paper 37403010 Paper 37395891 Paper 37359363 Paper 37330524 Paper 37277117 Paper 37174109 Paper 37173940 Paper 37152948 Paper 37147884 Paper 37076478 Paper 37001620 Paper 36995227 Paper 36992320 Paper 36895479 Paper 36878440 Paper 36777346 Paper 36773885 Paper 36574841 Paper 36333465 Paper 36285717 Paper 36241136 Paper 36207010 Paper 36198068 Paper 36081866 Paper 35922426 Paper 35881476 Paper 35876501 Paper 35715555 Paper 35700525 Paper 35524112 Paper 35439366 Paper 35390742 Paper 35383602 Paper 35349600 Paper 35307526 Paper 35210514 Paper 35197200 Paper 35158004 Paper 35137455 Paper 35068192 Paper 35054859 Paper 34951964 Paper 34809478 Paper 34778567 Paper 34769141 Paper 34762526 Paper 34757588 Paper 34596508 Paper 34585846 Paper 34569104 Paper 34566253 Paper 34503090 Paper 34440606 Paper 34348968 Paper 34338974 Paper 34337974 Paper 34278710 Paper 34066484 Paper 34060910 Paper 33970941 Paper 33933330 Paper 33878033 Paper 33818732 Paper 33812716 Paper 33795658 Paper 33675163 Paper 33618957 Paper 33598686 Paper 33586292 Paper 33505413 Paper 33420631 Paper 33385950 Paper 33316429 Paper 33274676 Paper 33239241

Abstract

MM is a presently difficult-to-cure plasma cell malignancy that accumulates in the bone marrow (BM) and is clinically preceded by the asymptomatic plasma cell dyscrasias (PCD) known as monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM), which are distinguished from MM based on the lack of end-organ damage. MGUS occurs in 3% of the general population over the age of 50 and is typically detected. Individual with MGUS do not have any signs or symptoms. However, the risk of MGUS progressing to MM increases by ~1% each year. SMM is an intermediate stage between MGUS and MM with a higher risk of progression to MM, especially during the first five years. The clinical symptoms of MM include calcium dysregulation, renal dysfunction, anemia, and bone lesions (CRAB).

View original record on NIH RePORTER →